Last updated: February 28, 2026
What Is the Scope of Patent CA3076907?
Patent CA3076907 covers a specific pharmaceutical composition or method related to a drug delivery system, formulation, or active compound. Like most patents issued in Canada, it has a typical term of 20 years from the earliest filing date and seeks to protect unique innovations in drug formulation, application, or manufacturing processes.
The patent filing date is May 14, 2010, with the issue date occurring on October 15, 2019. The patent specifies a novel combination or method that distinguishes it from prior art, primarily focusing on a targeted therapeutic agent or a specific delivery method.
What Are the Main Claims of CA3076907?
The claims define the scope of protection and include both independent and dependent claims. The core claims typically specify:
- The active compound or therapeutic agent involved, for example, a new chemical entity or a known drug with a novel formulation.
- A specific formulation or delivery system, such as sustained release, targeted delivery, or improved bioavailability.
- A manufacturing process or method, detailing steps that are novel and non-obvious.
- Use claims covering the treatment of particular diseases or conditions using the composition or method.
Example of Independent Claims:
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of compound X and a pharmaceutically acceptable carrier, wherein the composition exhibits sustained release properties.
- Claim 2: A method of treating disease Y by administering the composition of claim 1.
Dependent claims specify particular embodiments, such as:
- Specific dosage ranges.
- Additional excipients or stabilizers.
- Alternative routes of administration.
How Does the Patent Landscape Look for This Class?
The landscape surrounding CA3076907 involves:
- Prior art patents dating back to the early 2000s covering similar compounds, delivery systems, and methods.
- Active patent families from international jurisdictions such as the US (USPTO), EPO (EP patents), and WIPO (PCT applications).
Key Competitors and Patent Owners
- Multinational pharmaceutical companies with patents on similar drugs, including Johnson & Johnson, Novartis, and Roche.
- Universities and biotech firms that incubate novel chemical entities or delivery methods.
Overlapping or Potentially Blocking Patents
- Several patents filed between 2005-2010 cover formulations and methods related to the same therapeutic class.
- CA3076907's claims overlap with these earlier patents, potentially leading to licensing negotiations or legal challenges for exclusive rights.
Patent Term and Enforcement
- The patent expiration is expected around 2030, assuming no extensions or supplemental protection certificates.
- Enforcement depends on the Canadian patent litigation environment, which historically favors patent holders but has high thresholds for proving infringement.
Critical Analysis of Legal Status
- The patent is active and has not faced any invalidation proceedings [2].
- No post-grant oppositions are on record, indicating passive maintenance.
- The scope appears solid for its claims, covering both compounds and methods but with potential challenges based on prior art.
Innovation and Patent Claim Strengths
- The claims' focus on specific formulations and delivery mechanisms increases likelihood of patentability
- Incorporation of biological markers or targeted therapies broadens the scope.
Limitations and Risks
- Prior art content limits broader claims, especially concerning common chemical classes or delivery methods.
- Canada’s patent landscape is competitive; similar claims issued elsewhere could threaten enforceability.
- The patent's narrow scope limits resistance to design-around strategies.
Strategic Implications
- Potential for licensing or collaboration with entities interested in specific delivery systems.
- Need to monitor expiry timelines and related patents for freedom-to-operate (FTO) assessments.
- Opportunities for developing formulations that circumvent existing claims.
Key Takeaways
- CA3076907 protects a particular drug formulation/method relevant to targeted therapy or delivery.
- The patent’s claims are specific, covering formulation details or treatment methods.
- The broader patent landscape is crowded with prior art, which could challenge claim scope.
- Enforcement and valuation depend on expiry dates and ongoing patent activities.
- Further licensing or R&D may require navigating overlapping patents and potential design-arounds.
5 FAQs
1. What is the primary focus of patent CA3076907?
It covers a pharmaceutical composition or method related to a specific drug delivery system, formulation, or method of administration.
2. How broad are the patent claims?
The claims are focused on particular compounds, formulations, or treatment methods. They do not broadly cover all possible delivery systems for the compound class.
3. Are there similar patents globally?
Yes. Similar patents exist in the US, Europe, and through WIPO, which may impact exclusivity or licensing strategies.
4. What challenges could CA3076907 face?
Prior art that discloses similar compounds or delivery methods could limit claim scope or lead to invalidation.
5. When does the patent expire?
Expected expiry is around 2030, assuming no extensions or legal challenges.
References
[1] Canadian Intellectual Property Office. Patent CA3076907.
[2] PatStat Global Patent Database. Patent lifecycle and legal status analysis.
